Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Launched by QUEEN MARY HOSPITAL, HONG KONG · Oct 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for a condition called paronychia, which is an infection or irritation around the nails that can happen in some patients taking medications for lung cancer. Specifically, the study will test how effective a combination of two treatments—topical timolol eye drops and betamethasone cream—are for helping patients who have developed paronychia while being treated with specific lung cancer medications known as EGFR-TKIs and ALK-TKIs.

To be eligible for this trial, participants need to be at least 18 years old and diagnosed with advanced non-small cell lung cancer. They must also have experienced paronychia as a side effect of their cancer treatment. The trial is currently recruiting participants, and those who join will receive the new treatment to see if it helps improve their symptoms of paronychia. It’s important for potential participants to talk to their healthcare provider to understand if this trial is right for them.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1. Aged 18 years or above, either males or females.
• • 2. Received EGFR-TKI and ALK-TKI, namely gefitinib, erlotinib, afatinib, osimertinib, amivantamab, dacomitinib, mobocertinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib for the treatment of non-small cell lung cancer.
• • 3. Paronychia (fingernails, toenails, or both) as an adverse event from EGFR-TKI use
• • 4. Written informed consent obtained from patient
• • 5. Subjects are diagnosed with advanced non-small cell lung cancer
• • Exclusion criteria
• • 1. 1. Age below18
• • 2. 2. Patients who are allergic to, or contraindicated to topical timolol use
• • 3. 3. Pregnant women or nursing mother
• • 4. 4. Non-consenting patients
• • 5. 5. Subjects are not diagnosed with advanced non-small cell lung cancer